On November 5, 2025, NewAmsterdam Pharma announced its third-quarter financial results and provided a corporate update. The company reported a significant regulatory milestone with the European Medicines Agency’s acceptance of marketing authorization applications for obicetrapib and its fixed-dose combination with ezetimibe. Despite a decrease in revenue and an increase in net loss compared to the previous year, NewAmsterdam continues to advance its clinical development strategy and build global infrastructure to support the potential launch of obicetrapib. The company also highlighted its ongoing trials and upcoming milestones, emphasizing its commitment to providing a differentiated therapy in the cardiovascular market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.